Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation [17]

Leukemia

Volumn 19, Issue 3, 2005, Pages 490-492

  Lindemann, M ^a   Schuett, P ^a   Moritz, T ^a   Ottinger, H D ^a   Opalka, B ^a   Seeber, S ^a   Nowrousian, M R ^a   Grosse Wilde, H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGENIC AGENT; THALIDOMIDE;

AGE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RELAPSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MEGADOSE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; LETTER; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE TRANSFORMATION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; AUTOTRANSPLANTATION; DOSE RESPONSE; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNITY, CELLULAR; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 15044338886     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403633     Document Type: Letter

References (8)

1. Wendelbo O, Nesthus I, Sjo M, Ernst P, Bruserud O. Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Leuk Res 2004; 28: 461-468.
2. Malphettes M, Carcelain G, Saint-Mezard P, Leblond V, Altes HK, Marolleau JP et al. Evidence for naive T-cell repopulation despite thymus irradiation after autologous transplantation in adults with multiple myeloma: role of ex vivo CD34+ selection and age. Blood 2003; 101: 1891-1897.
3. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93: 2411-2419.
4. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000; 108: 805-816.
5. Lindemann M, Witzke O, Winterhagen T, Ross B, Kreuzfelder E, Reinhardt W et al. T cell function after IL-2 therapy in HIV-infected patients is correlated with serum cortisol concentrations. AIDS 2004; 18: 2001-2007.
6. Shannon EJ, Sandoval FG. Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine - dependence on the primary stimulant. Int Immunopharmacol 2002; 2: 1143-1153.
7. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
8. De Rosa L, Anghel G, Pandolfi A, Riccardi M, Amodeo R, Majolino I. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. Int J Hematol 2004; 79: 85-91.